Autophagy dysfunction in Parkinson's Disease by VPS35 D620N
VPS35 D620N 治疗帕金森病的自噬功能障碍
基本信息
- 批准号:9475532
- 负责人:
- 金额:$ 11.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-15 至 2020-06-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAmyotrophic Lateral SclerosisAttentionAutophagocytosisCancer cell lineCell Culture TechniquesCell DeathCell modelCell physiologyCellsCharacteristicsClinicalComplexDementiaDevelopmentDiseaseEWSR1 geneEnvironmentExcisionExhibitsFunctional disorderGeneticGoalsHela CellsInvestigationKnowledgeLeadLinkMalignant neoplasm of cervix uteriMass Spectrum AnalysisMediatingMetabolismModelingMolecularMutationNerve DegenerationNeurodegenerative DisordersOrganellesOutcomeParkinson DiseaseParkinsonian DisordersPathogenesisPathway interactionsPatientsPositioning AttributePre-Clinical ModelProcessProteinsRNARNA-Binding ProteinsReportingResearchSignal PathwayStudentsSubstantia nigra structureTestingUniversitiesValidationWorkalpha synucleinbasecombatdisease-causing mutationdopaminergic neuronexperiencegraduate studentimprovedinhibition of autophagyinsightmacromoleculemotor disordermotor symptomneuron lossnovelnovel therapeuticsprogramsprotein aggregatepublic health relevancesarcomatherapy developmenttranscriptometranscriptome sequencingundergraduate student
项目摘要
DESCRIPTION (provided by applicant): Parkinson's disease (PD) is the most common motor disease in the USA. The primary clinical motor symptoms of PD result from loss of dopaminergic (DA) neurons in the substantia nigra with autophagy dysfunction being closely linked to this disease. Autophagy is a cellular process responsible for degradation of organelles, macromolecules, and protein aggregates. In PD, characteristic toxic protein aggregates of primarily alpha-synuclein are believed to be substrates for autophagic removal and clearance by autophagy improves preclinical model outcomes. Therefore, modulation of autophagy may be an effective strategy to combat PD. Recently, a PD-causing mutation in VPS35 (D620N) was reported to block autophagy. However, preliminary investigation by other groups into a causal mechanism was limited to canonical VPS35 protein interactors in HeLa cells. To overcome these limitations we have performed an unbiased screen using mass spectrometry and RNA sequencing (RNA seq) to identify key protein interactors and pathways in a widely-used cellular model of PD. We have discovered that VPS35 protein interactors show a high enrichment for RNA- binding proteins including several known or suspected to be causal for amyotrophic lateral sclerosis. Additionally, the D620N mutation resulted in a dramatic decrease in RNA-binding protein interaction. From our screen, Fused in Sarcoma (FUS) and Ewing sarcoma breakpoint region 1 (EWSR1) have emerged as lead candidates for mediating VPS35 D620N autophagy dysfunction. Based upon RNA-binding protein interaction, we examined the transcriptome of VPS35 WT and D620N cells and found changes indicative of alterations in RNA metabolism and autophagy. We hypothesize that VPS35 D620N inhibits autophagy and causes cell death by regulating RNA metabolism through RNA-binding protein activity. We propose testing our hypothesis by determining if autophagy dysfunction and neurodegeneration by VPS35 D620N is caused by altered RNA-binding protein activity and establish that VPS35 D620N causes transcriptome changes that facilitate autophagy dysfunction.
描述(由申请人提供):帕金森病(PD)是美国最常见的运动疾病。PD的主要临床运动症状是由于黑质中多巴胺能(DA)神经元的损失,自噬功能障碍与这种疾病密切相关。自噬是细胞内细胞器、大分子和蛋白质聚集体降解的过程。在PD中,主要是α-突触核蛋白的特征性毒性蛋白聚集体被认为是自噬去除的底物,并且通过自噬的清除改善了临床前模型结果。因此,调节自噬可能是对抗PD的有效策略。最近,VPS 35(D 620 N)中引起PD的突变被报道可以阻断自噬。然而,其他小组对因果机制的初步研究仅限于HeLa细胞中的典型VPS 35蛋白相互作用物。为了克服这些限制,我们使用质谱和RNA测序(RNA seq)进行了无偏筛选,以确定广泛使用的PD细胞模型中的关键蛋白质相互作用物和途径。我们已经发现VPS 35蛋白相互作用物显示出RNA结合蛋白的高度富集,包括几种已知或怀疑是肌萎缩性侧索硬化症的病因的RNA结合蛋白。此外,D 620 N突变导致RNA结合蛋白相互作用的急剧减少。从我们的筛选中,融合肉瘤(FUS)和尤文肉瘤断点区1(EWSR 1)已成为介导VPS 35 D 620 N自噬功能障碍的主要候选者。基于RNA结合蛋白相互作用,我们检查了VPS 35 WT和D 620 N细胞的转录组,发现了指示RNA代谢和自噬改变的变化。我们假设VPS 35 D 620 N通过RNA结合蛋白活性调节RNA代谢来抑制自噬并导致细胞死亡。我们建议通过确定VPS 35 D 620 N引起的自噬功能障碍和神经变性是否是由RNA结合蛋白活性改变引起的来测试我们的假设,并确定VPS 35 D 620 N引起促进自噬功能障碍的转录组变化。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brad Morrison其他文献
Brad Morrison的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brad Morrison', 18)}}的其他基金
Harnessing endothelial cell transdifferentiation for cardiovascular therapy
利用内皮细胞转分化进行心血管治疗
- 批准号:
10513527 - 财政年份:2022
- 资助金额:
$ 11.86万 - 项目类别:
VPS35 D620N inhibits autophagy through disrupted hyaluronic acid-CD44 signaling
VPS35 D620N 通过破坏透明质酸-CD44 信号传导抑制自噬
- 批准号:
10226312 - 财政年份:2014
- 资助金额:
$ 11.86万 - 项目类别:
VPS35 D620N inhibits autophagy through disrupted hyaluronic acid-CD44 signaling
VPS35 D620N 通过破坏透明质酸-CD44 信号传导抑制自噬
- 批准号:
10415177 - 财政年份:2014
- 资助金额:
$ 11.86万 - 项目类别:
相似海外基金
Amyotrophic Lateral Sclerosis: treating the circuit behind the disease
肌萎缩侧索硬化症:治疗疾病背后的回路
- 批准号:
MR/Y014901/1 - 财政年份:2024
- 资助金额:
$ 11.86万 - 项目类别:
Research Grant
Dysregulation of RNA processing as a driver of motor neuron dysfunction in Amyotrophic Lateral Sclerosis
RNA 加工失调是肌萎缩侧索硬化症运动神经元功能障碍的驱动因素
- 批准号:
MR/Y014286/1 - 财政年份:2024
- 资助金额:
$ 11.86万 - 项目类别:
Research Grant
Fasciculation IN Amyotrophic Lateral Sclerosis Using MUMRI (FINALSUM)
使用 MUMRI 治疗肌萎缩侧索硬化症的肌束颤动 (FINALSUM)
- 批准号:
MR/Y503502/1 - 财政年份:2024
- 资助金额:
$ 11.86万 - 项目类别:
Research Grant
I-Corps: Developing A Blood-Based Biomarker for the Detection and Monitoring of Amyotrophic Lateral Sclerosis
I-Corps:开发一种基于血液的生物标志物,用于检测和监测肌萎缩侧索硬化症
- 批准号:
2317745 - 财政年份:2023
- 资助金额:
$ 11.86万 - 项目类别:
Standard Grant
Targeted immunotherapy for amyotrophic lateral sclerosis and frontotemporal dementia
肌萎缩侧索硬化症和额颞叶痴呆的靶向免疫治疗
- 批准号:
10759808 - 财政年份:2023
- 资助金额:
$ 11.86万 - 项目类别:
Resolving the Role of Neuronal STING in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
解决神经元 STING 在肌萎缩侧索硬化症和额颞叶痴呆中的作用
- 批准号:
10606865 - 财政年份:2023
- 资助金额:
$ 11.86万 - 项目类别:
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
开发 CM-CS1 CAR Treg 治疗肌萎缩侧索硬化症 (ALS)
- 批准号:
10696512 - 财政年份:2023
- 资助金额:
$ 11.86万 - 项目类别:
Metrics for Brain Controlled Communication: A comprehensive review of clinical outcome assessments for communication brain computer interfaces in amyotrophic lateral sclerosis
脑控制通信指标:肌萎缩侧索硬化症通信脑机接口临床结果评估的全面综述
- 批准号:
10848139 - 财政年份:2023
- 资助金额:
$ 11.86万 - 项目类别:
The biochemical stratification of amyotrophic lateral sclerosis
肌萎缩侧索硬化症的生化分层
- 批准号:
MR/Y001095/1 - 财政年份:2023
- 资助金额:
$ 11.86万 - 项目类别:
Fellowship
The Gut Microbiota as a Contributor to Sexual Dimorphism in Amyotrophic Lateral Sclerosis
肠道微生物群是肌萎缩侧索硬化症性别二态性的一个促成因素
- 批准号:
488892 - 财政年份:2023
- 资助金额:
$ 11.86万 - 项目类别:
Operating Grants